Somatropin Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL

Reference Brands: Genotropin (EU), Norditropin (EU/India)

Category: Women's Health

Somatropin is a Women's Health product available as injection (prefilled syringe) in strengths 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL. It corresponds to the reference brands Genotropin (EU), Norditropin (EU/India). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production or secretion of growth hormone (GH) from the pituitary gland. Growth hormone plays a vital role in normal growth, metabolism, and overall body development. When the body does not produce enough GH, it can lead to growth failure in children and a range of metabolic and physical changes in adults. Globally, childhood growth hormone deficiency is estimated to affect approximately 1 in 4,000 to 10,000 children, while prevalence rates may vary by region. Adult growth hormone deficiency is less common but still represents an important endocrine disorder requiring proper diagnosis and management.

GHD is typically classified into two main types: childhood-onset growth hormone deficiency (CO-GHD) and adult-onset growth hormone deficiency (AO-GHD). Childhood-onset cases may be congenital, acquired, or idiopathic. Congenital GHD is usually associated with genetic abnormalities that affect the synthesis of growth hormone or the function of growth hormone–releasing hormone receptors. Acquired GHD may occur due to tumors affecting the pituitary gland or hypothalamus, surgical procedures, radiation therapy, brain injuries, infections such as meningitis, or other damage to the brain.

In adults, growth hormone deficiency often develops as a result of pituitary tumors, medical treatments affecting the pituitary region, or as a continuation of untreated childhood-onset GHD. In some cases, GHD occurs alone, while in others it may be associated with deficiencies of additional pituitary hormones. Early diagnosis and appropriate treatment are important to manage symptoms, support normal growth in children, and improve metabolic health and quality of life in affected individuals.